STERIS plc
In the published model solve dated 2026-Q2, anchored at $233.78, STERIS plc (STE) is priced for +16.1% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 11, 2026 from SEC EDGAR filings.
• STERIS is a sterilization and infection-prevention leader whose value is the recurring consumables and service tied to its installed base, growing about 9% across all three segments with Applied Sterilization Technologies up 13% in the first quarter. • The biggest risk is valuation against a rising cost base: at about 27 times trailing earnings only peer-multiple and growth methods reach the roughly $215.89 price, while a raised tariff hit of about $45 million kept management from lifting EPS
Is STE overvalued? See what's priced in →
816 institutional managers reported holding STE in 13F filings for the quarter ended 2026-03-31. 67 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 2.0M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (2.6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
STE's share count grew 8.9% over the past five years even with $812.26M spent on repurchases. It pays a dividend, and has paid one every year in our records (8 and counting), raised 7 years straight; the current rate is $2.46 a share annually. Cash returned over the past three years: $615.82M in dividends and $449.86M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at STE over the trailing three years. Absence is a fact about the company, not a signal. 14 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
STE's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-09 | +1.0% | -0.9% |
| 2023-11-08 | -5.1% | +8.6% |
| 2024-02-09 | -2.5% | -9.0% |
| 2024-05-30 | +6.2% | +8.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
STE's latest 8-K filings: 2026-08-06 (items 5.07); 2026-08-05 (items 2.02, 2.05, 9.01); 2026-05-11 (items 2.02, 9.01); 2026-05-07 (items 5.02, 7.01, 9.01); 2026-04-06 (items 5.02).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 11, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.